Making Sense of the Difference-in-Difference Design
This Guide to Statistics and Methods describes the difference-in-differences study design.
This Guide to Statistics and Methods describes the difference-in-differences study design.
This Clinical Insights describes the process for initiating buprenorphine treatment for patients with opioid use disorder.
An infant boy presented with generalized rash, fever, and severe skin pain. What is your diagnosis?
A 1-day-old, healthy, full-term boy born by cesarean delivery for placental abruption to a 31-year-old primigravid mother was noted at birth to have an erythematous patch on his lower lip.
Importance Although treatment for chronic urticaria (CU) has improved over the past decades, evidence regarding costs and net benefits associated with these treatment strategies have yet to be comprehensively characterized and synthesized. Objective To summarize the cost and cost-effectiveness of CU management…
Importance Renal cell carcinoma (RCC) is a common malignancy, with an estimated 434 840 incident cases worldwide in 2022. In the US, it is the sixth most common cancer among males and ninth among females. Observations Clear cell RCC is the most common…
This JAMA Clinical Guidelines Synopsis summarizes the 2023 American Association for the Study of Liver Diseases practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Importance The use of real-world data (RWD) external control arms in prospective studies is increasing. The advantages, including the immediate availability of a control population, must be balanced with the requirements of meeting evidentiary standards. Objective To address the question of whether…
Historically, most discussions about nonhuman animal experimentation consider what has become known as the 3 R’s: refinement, reduction, and replacement. Refinement and reduction receive the most attention, but recent modeling advances suggest that suitable replacement of nonhuman animal testing would…
This article reviews the design of a recently published randomized controlled trial (RCT) on immediate vs delayed access to gender-affirming hormones for transgender and gender-diverse (TGD) people and outlines key learning points that clinicians should know about how RCTs can…
© 2026
American Board of Medical Specialties | Policies | Sitemap | Terms of Use | www.abms.org